Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

ssion (EC) also approved the use of Soliris(TM) (eculizumab) for the treatment of patients with PNH. Soliris is the first therapy approved in Europe for the treatment of PNH and was the first medicinal product to receive EU approval under the EMEA Accelerated Assessment Procedure.

Important Safety Information

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, nasopharyngitis (a runny nose), back pain and nausea. Treatment with Soliris should not alter anticoagulant management because the effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established.

The U.S. product label for Soliris also includes a boxed warning: "Soliris increases the risk of meningococcal infections. Vaccinate patients with a meningococcal vaccine at least two weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use. Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary." Two out of 196 vaccinated PNH patients treated with Soliris experienced a serious meningococcal infection.

Prior to beginning Soliris therapy, all patients and their prescribing physicians will be enrolled in the Soliris Safety Registry which is part of a special risk management program that involves initial and continuing education and long-term monitoring for detection of new safety findings.

Please see full prescribing information at http://www.soliris.net.

About Alexion

Alexion Pharmaceuticals, Inc. is a biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. The Company is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a w
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)...  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... the approved abbreviated new drug application ("ANDA") for ... previously marketed by Teva Pharmaceuticals.  According to IMS ... approximately $39 million in 2014.   ... of ANI Pharmaceuticals, stated, "This acquisition further expands ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4q7gwz/india_pharma ) ... Outlook 2015: Accelerating growth to the next level - ... to their offering. Domestic sales improved ... caused by the market,s reaction to the new drug ... to be healthy, as the momentum continues and improving ...
(Date:3/5/2015)... N.J. , March 5, 2015 Soligenix, ... stage biopharmaceutical company committed to developing products that address ... and biodefense, announced today that its President and Chief ... give a corporate presentation at the 27 th ... , on Tuesday, March 10, 2015 at 1:00 ...
Breaking Medicine Technology:ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3
... GHENT, Belgium, December 1, 2011 ... Programs into Clinical Development arGEN-X, a ... human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, ... (USD 37 million) Series B fundraising round, which was ...
... Nov. 30, 2011  Heart IT, the global leader that ... workstation and Johns Hopkins Medicine, announced the award of ... images in the Nationwide Health Information Network (NHIN). The ... of the National Office of the Coordinator for Health ...
Cached Medicine Technology:arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round 2arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round 3arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B Round 4Heart IT and Johns Hopkins Medicine Announce the Award of NIH Grant to Include Images in the Nationwide Health Information Network (NHIN) 2
(Date:3/6/2015)... (PRWEB) March 06, 2015 Truly Nolen, ... pleased to announce the grand opening of their first ... Charlotte area down to the Fort Mill – Rock ... on February 27th, 2015 at their new location. ... 35 years of collective experience in the pest control ...
(Date:3/6/2015)... Austin, TX (PRWEB) March 06, 2015 ... transformational publishing company, created a unique ‘energy’ experiment ... people’s lives. , After quick ‘5 ... in more than 150+ countries reported their life ... of respondents reported positive results. , According to ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Fluid Running® ... Marathon qualifier, developed the Fluid Running® method ... before the Chicago marathon. She hit upon the trifecta ... group run, and a maximum-resistance, deep water running technique. ... unique no-impact, deep water running workout that made the ...
(Date:3/5/2015)... In 2014, the FDA approved 44 drugs, with ... scoring 4 drug approvals in the USA. The infectious ... drug products, followed by oncology therapy with 18% of ... CDK inhibitors keep on attracting large-cap pharmacos. Nivolumab and ... metastatic melanoma, and at present, they are being investigated ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 AxoGen, ... focused on the peripheral nerve repair market, reported record ... December 31, 2014 compared to $2.98 million in the ... its growth strategies. , “Our strong fourth quarter ... peripheral nerve repair products which is driving increased surgeon ...
Breaking Medicine News(10 mins):Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4
... 27 An effective,cross-functional team lays the groundwork ... both initially and long-term. Leading,pharma companies calculate that ... for half of a drug,s success with the,other ... compound, according,to a study by Best Practices, LLC. ...
... The Clinical Trials Directive, which came into force ... harmonised framework for clinical drug research across Europe, ... findings presented at the European Cancer Conference (ECCO ... Hartmann, from European Consulting and Contracting in Oncology, ...
... 27 - Call for international Berthold ... Submissions Applications and proposals are now being ... developers and,researchers who do innovative work in the ... foundation Berthold Leibinger Stiftung is granted for,innovations pertaining ...
... Rendell,recently appointed Richard Snyder, M.D., senior vice president ... the state,s Chronic Care,Commission. Snyder took his oath ... other commission appointees during its first meeting. ... for Pennsylvanians,living with chronic health conditions such as ...
... Spain: In the largest and most rigorous study to ... found that marriages are no more likely than normal ... testicular cancer. , In fact, the study, presented today ... 14) in Barcelona, found most types of cancer resulted ...
... Has Gone Pink To Promote Breast Cancer Awareness, ... entered into,a partnership with Susan G. Komen for the ... with a spreader that features the pink breast,cancer awareness ... of National Breast Cancer Awareness Month and the program ...
Cached Medicine News:Health News:Creating Effective Cross-Functional Teams for Pharmaceutical Commercialization Success 2Health News:Clinical Trials Directive still hampering academic medical research 2Health News:Clinical Trials Directive still hampering academic medical research 3Health News:Prize for Cutting-Edge Laser Innovations 2Health News:Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission 2Health News:Governor Rendell Appoints Dr. Richard Snyder of Independence Blue Cross to Chronic Care Commission 3Health News:Couples more likely to divorce if spouse develops cervical or testicular cancer 2Health News:Susan G. Komen for the Cure Partners With the Original Butter Bell(R) Crock Developer 2
Tryptone is the pancreatic digest of casein used as a nitrogen source for bacteria. Ideal for general bacteriological use with a variety of microorganisms. Tryptone is guaranteed BSE-Free....
... 10k units Pen.,10k ug Strept. ... Cell Culture Reagent and Buffer ... with cGMP regulations and are ... compatibility. , Typical Properties, Sterility ...
... G) inhibits bacterial growth ... Streptomycin belongs to the ... bacterial growth by inhibiting ... used for prevention and ...
... of Penicillin, Steptomycin, and Amphotericin is ... of cell culture contamination; bacteria (gram ... fungi; when used at a concentration ... is a combination of all three ...
Medicine Products: